Related Experiment Video
Updated: Jun 17, 2026
10:37
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Is melatonin involved in the irritable bowel syndrome?
P Radwan1, B Skrzydlo-Radomanska, K Radwan-Kwiatek
1Department of Gastroenterology, Medical University of Lublin, Poland.
Summary
Melatonin metabolite 6-sulphatoxymelatonin (6-SMLT) levels were lower in patients with irritable bowel syndrome (IBS). This suggests altered melatonin metabolism may play a role in IBS development.
Area of Science:
- Gastroenterology
- Endocrinology
- Metabolic Research
Background:
- Melatonin is produced in the gastrointestinal tract, but its role in digestive health and disease is not fully understood.
- Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with unclear pathophysiology.
- Investigating melatonin's role could offer new insights into IBS mechanisms.
Purpose of the Study:
- To investigate the urinary excretion of 6-sulphatoxymelatonin (6-SMLT), a key melatonin metabolite, in patients with IBS.
- To compare 6-SMLT levels between constipation-predominant IBS (C-IBS), diarrhea-predominant IBS (D-IBS), and healthy controls.
- To explore potential sex-based differences in melatonin metabolism within IBS subtypes.
Main Methods:
- Study included 67 participants (20-45 years old): 21 with C-IBS, 24 with D-IBS, and 22 healthy controls.
- Diurnal urine samples were collected and analyzed for 6-SMLT concentration using ELISA.
- Creatinine levels were measured, and the 6-SMLT/creatinine ratio was calculated to normalize for urine concentration.
Main Results:
- Patients with both C-IBS and D-IBS showed significantly lower urinary 6-SMLT/creatinine levels compared to healthy controls (p=0.002 and p=0.003, respectively).
- No significant difference in 6-SMLT/creatinine levels was found between C-IBS and D-IBS groups.
- A notable difference was observed in C-IBS patients, with women exhibiting higher 6-SMLT/creatinine levels than men (p=0.04).
Conclusions:
- Lower urinary excretion of 6-SMLT in IBS patients suggests altered melatonin metabolism may be implicated in the pathogenesis of the disorder.
- The findings indicate that melatonin secretion and metabolism could be a contributing factor to IBS.
- Further research is warranted to elucidate the specific mechanisms and potential therapeutic implications of melatonin in IBS.
Related Concept Videos
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...